Jaguar Health, Inc. (JAGX)
NASDAQ (CM) NASDAQ (CM) Primary 
Jaguar Health's stock slides 68% after cancer trial fails to meet main goal
Jaguar Health Inc.'s stock JAGX, +0.23% tumbled 68% early Tuesday, after the biotech said a late-stage trial of a cancer drug failed to meet its main goal across all tumor types. San Francisco-based Jaguar said the Phase 3 trial of its crofelemer for prophylaxis of diarrhea in adult cancer patients with solid tumors receiving targeted therapy with or without standard chemotherapy did not meet its primary endpoint.
Jaguar Health Reports Phase 3 OnTarget Trial Results for its Cancer Supportive Care Drug Crofelemer
Initial results of unprecedented trial including 10 different tumor types indicate that OnTarget did not meet its primary endpoint across all tumor types. Trial did reveal clinically relevant signals for crofelemer in prespecified subgroups of patients with breast and respiratory cancer, including lung cancer.
Jaguar Health to Report Phase 3 OnTarget Trial Results for Its Cancer Supportive Care Drug Crofelemer on July 23rd and Hold Investor Webcast that Morning
Webcast on Tuesday, July 23rd at 8:30 AM Eastern will include updates on Jaguar's cancer supportive care portfolio, including participation from Jaguar scientific team, patient advocates, and leading oncology experts on cancer therapy-related diarrhea (CTD) and oral mucositis; Click here to register for webcast Jaguar expands Make Cancer Less Shitty (MCLS) patient advocacy program to incorporate select group of MCLS Ambassadors - cancer survivors who understand the realities of cancer and are no longer willing to accept debilitating side effects of cancer treatments as an acceptable trade-off for survival Cancer patients with diarrhea are 40% more likely to discontinue their therapy; oral mucositis affects up to 40% of patients undergoing chemotherapy and approximately 90% of those receiving chemoradiation for head and neck cancers, with more than one-third of patients discontinuing cancer treatment because of the condition SAN FRANCISCO, CA / ACCESSWIRE / July 18, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") today announced that it will hold an investor webcast on Tuesday, July 23, 2024 at 8:30 AM Eastern to review results for the company's pivotal phase 3 OnTarget trial of crofelemer for prophylaxis of diarrhea in adult cancer patients with solid tumors receiving targeted therapy, with or without standard chemotherapy. A press release announcing the results will be issued that morning, prior to the webcast.
Jaguar Health Reports Approval of All Proposals at June 2024 Annual Meeting of Stockholders
Jaguar to report pivotal phase 3 OnTarget trial results for its cancer supportive care drug crofelemer on or before July 23, 2024 Investor webcast on or before July 23 will include updates on Jaguar's cancer supportive care portfolio, including participation from Jaguar scientific team, patient advocates, and leading oncology experts on cancer therapy-related diarrhea and oral mucositis In honor of World Rainforest Day (June 22), Jaguar is proud to share RealPharma podcast interview with ethnobotanist Dr. Steven King SAN FRANCISCO, CA / ACCESSWIRE / June 21, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced the voting results of the Company's Annual Meeting of Stockholders held June 21, 2024 (the "Annual Meeting"). Five proposals were submitted to and approved by the stockholders of the Company at the Annual Meeting.
Jaguar Health to Report Pivotal Phase 3 OnTarget Trial Results for its Cancer Supportive Care Drug Crofelemer on or Before July 23, 2024
Investor webcast on or before July 23 will include updates on Jaguar's cancer supportive care portfolio, including participation from Jaguar scientific team, patient advocates, and leading oncology experts on cancer therapy-related diarrhea (CTD) and oral mucositis Cancer patients with diarrhea are 40% more likely to discontinue their therapy, and up to 40% of cancer patients experience the painful side effect of oral mucositis SAN FRANCISCO, CA / ACCESSWIRE / June 12, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") today announced that it will hold an investor webcast on or before July 23, 2024 to provide results for the company's pivotal phase 3 OnTarget trial of crofelemer for prophylaxis of diarrhea in adult cancer patients with solid tumors receiving targeted therapy, with or without standard chemotherapy. The webcast, which will provide updates on Jaguar's advancing cancer supportive care portfolio, will include members of Jaguar's scientific team, patient advocates, and leading oncology experts on two of the most common and intolerable side effects of cancer therapy: CTD and oral mucositis.
Why Is Jaguar Health (JAGX) Stock Down 40% Today?
Jaguar Health (NASDAQ: JAGX ) stock is falling on Monday as the company prepares for a reverse stock split later this week. Jaguar Health is going to enact a one-for-60 reverse stock split on Thursday.
Jaguar Health, Inc. Announces Reverse Stock Split
Reverse split approved at April 2024 Special Meeting of Stockholders Shares of Jaguar Health common stock to begin trading on split-adjusted basis on May 23, 2024 SAN FRANCISCO, CA / ACCESSWIRE / May 17, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that the Company will effect a reverse stock split of its issued and outstanding voting common stock ("Common Stock"), at an exchange ratio of 1-for-60, on Thursday, May 23, 2024 (the "Effective Date") in order to support the Company's compliance with Nasdaq's listing standards. The Company's Common Stock will begin trading on a split-adjusted basis when the market opens on the Effective Date and will remain listed on The Nasdaq Capital Market under the symbol "JAGX".
